A Phase 1, Randomized Ascending Single-Dose Study of Antagonist Anti-Human CD40 ASKP1240 in Healthy Subjects
Article first published online: 28 JAN 2013
© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 13, Issue 4, pages 1040–1046, April 2013
How to Cite
Goldwater, R., Keirns, J., Blahunka, P., First, R., Sawamoto, T., Zhang, W., Kowalski, D., Kaibara, A. and Holman, J. (2013), A Phase 1, Randomized Ascending Single-Dose Study of Antagonist Anti-Human CD40 ASKP1240 in Healthy Subjects. American Journal of Transplantation, 13: 1040–1046. doi: 10.1111/ajt.12082
- Issue published online: 30 MAR 2013
- Article first published online: 28 JAN 2013
- Manuscript Accepted: 6 DEC 2012
- Manuscript Revised: 3 DEC 2012
- Manuscript Received: 25 OCT 2012
- Astellas Pharma Global Development
- 4Pharmacological and toxicological studies of a fully human antibody (4D11) against human CD40 in human samples in vitro and nonhuman primates in vivo. Am J Transplant 2005; 5(11 Suppl): 420., , , .
- 6Bioanalytical Validation Report IC-2009–001. Validation of an Analytical Method for the Determination of ASKP1240 in Human Serum using Electrochemiluminescence. February 26, 2010. Skokie, IL, USA: Astellas Pharma Global Development, Inc.; 2010..
- 7Bioanalytical Validation Report IC-2009–002. Validation of an analytical method for the screening, confirmation, and titer for the presence of anti-ASKP1240 antibodies in human serum using electrochemiluminescence detection. February 26, 2010. Skokie, IL, USA: Astellas Pharma Global Development, Inc.; 2010..
- 8Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation [abstract] Am J Transplant 2001; 1(Suppl 1): 191., , , .
- 10New approaches to prevent transplant rejection: Co-stimulation blockers anti-CD40L and CTLA41g. Drug Discov Today 2006; 3: 41–47., .